| 1. |
- Kanai, M, et al.
(författare)
-
- 2023
-
swepub:Mat__t
|
|
| 2. |
- Lyon, A., et al.
(författare)
-
Bridging HCI and Implementation Science for Innovation Adoption and Public Health Impact
- 2023
-
Ingår i: Conf Hum Fact Comput Syst Proc. - : Association for Computing Machinery. - 9781450394222
-
Konferensbidrag (refereegranskat)abstract
- Human computer interaction (HCI) and implementation science (IS) each have been applied to improve the adoption and delivery of innovative health interventions, and the two fields have complementary goals, foci, and methods. While the IS community increasingly draws on methods from HCI, there are many unrealized opportunities for HCI to draw from IS and to catalyze bidirectional collaborations. This workshop will explore similarities and differences between fields, with a goal of articulating a research agenda at their intersection.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Giménez-Arteaga, C., et al.
(författare)
-
Outshining in the spatially resolved analysis of a strongly lensed galaxy at z = 6.072 with JWST NIRCam
- 2024
-
Ingår i: Astronomy and Astrophysics. - 0004-6361 .- 1432-0746. ; 686
-
Tidskriftsartikel (refereegranskat)abstract
- We present JWST/NIRCam observations of a strongly lensed, sub-L∗, multiply imaged galaxy at z=6.072, with magnification factors μ³20 across the galaxy. The galaxy has rich HST, MUSE, and ALMA ancillary observations across a broad wavelength range. Aiming to quantify the reliability of stellar mass estimates of high redshift galaxies, we performed a spatially resolved analysis of the physical properties at scales of ~200 pc, inferred from spectral energy distribution (SED) modelling of five JWST/NIRCam imaging bands covering 0.16 μm < λrest < 0.63 μm on a pixel-by-pixel basis. We find young stars surrounded by extended older stellar populations. By comparing Hα+[Nâ¯II] and [Oâ¯III]+Hβ maps inferred from the image analysis with our additional NIRSpec integral field unit (IFU) data, we find that the spatial distribution and strength of the line maps are in agreement with the IFU measurements. We explore different parametric star formation history (SFH) forms with BAGPIPES on the spatially integrated photometry, finding that a double power-law (DPL) star formation history retrieves the closest value to the spatially resolved stellar mass estimate, and other SFH forms suffer from the dominant outshining emission from the youngest stars, thus underestimating the stellar mass - up to ~0.5 dex. On the other hand, the DPL cannot match the IFU-measured emission lines. Additionally, the ionising photon production efficiency may be overestimated in a spatially integrated approach by ~0.15 dex, when compared to a spatially resolved analysis. The agreement with the IFU measurements implies that our pixel-by-pixel results derived from the broadband images are robust, and that the mass discrepancies we find with spatially integrated estimates are not just an effect of SED-fitting degeneracies or the lack of NIRCam coverage. Additionally, this agreement points towards the pixel-by-pixel approach as a way to mitigate the general degeneracy between the flux excess from emission lines and underlying continuum, especially when lacking photometric medium-band coverage and/or IFU observations. This study stresses the importance of studying galaxies as the complex systems that they are, resolving their stellar populations when possible, or using more flexible SFH parameterisations. This can aid our understanding of the early stages of galaxy evolution by addressing the challenge of inferring robust stellar masses and ionising photon production efficiencies of high redshift galaxies.
|
|
| 7. |
- MacDonald, Amy M., et al.
(författare)
-
Maternal and child biomonitoring strategies and levels of exposure in western Canada during the past seventeen years : The Alberta Biomonitoring Program
- 2022
-
Ingår i: International journal of hygiene and environmental health. - : Elsevier BV. - 1438-4639 .- 1618-131X. ; 244
-
Tidskriftsartikel (refereegranskat)abstract
- The Alberta Biomonitoring Program (ABP) was created in 2005 with the initial goal of establishing baseline levels of exposure to environmental chemicals in specific populations in the province of Alberta, Canada, and was later expanded to include multiple phases. The first two phases focused on evaluating exposure in pregnant women (Phase One, 2005) and children (Phase Two, 2004–2006) by analyzing residual serum specimens. Phase Three (2013–2016) employed active recruitment techniques to evaluate environmental exposures using a revised list of chemicals in paired serum pools from pregnant women and umbilical cord blood. These three phases of the program monitored a total of 226 chemicals in 285 pooled serum samples representing 31,529 individuals. Phase Four (2017–2020) of the ABP has taken a more targeted approach, focusing on the impact of the federal legalization of cannabis on the exposure of pregnant women in Alberta to cannabis, as well as tobacco and alcohol using residual prenatal screening serum specimens. Chemicals monitored in the first three phases include herbicides, neutral pesticides, metals, metalloids, and micronutrients, methylmercury, organochlorine pesticides, organophosphate pesticides, parabens, phthalate metabolites, perfluoroalkyl substances (PFAS), phenols, phytoestrogens, polybrominated compounds, polychlorinated biphenyls (PCBs), dioxins and furans, polycyclic aromatic hydrocarbons (PAHs), and tobacco biomarkers. Phase Four monitored six biomarkers of tobacco, alcohol, and cannabis. All serum samples were pooled. Mean concentrations and 95% confidence intervals (CIs) were calculated for the chemicals detected in ≥25% of the sample pools. cross the first three phases, the data from the ABP has provided baseline exposure levels for the chemicals in pregnant women, children, and newborns across the province. Comparison within and among the phases has highlighted differences in exposure levels with age, geography, seasonality, sample type, and time. The strategies employed throughout the program phases have been demonstrated to provide effective models for population biomonitoring.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Celutkiene, Jelena, et al.
(författare)
-
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies : a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)
- 2020
-
Ingår i: European Journal of Heart Failure. - : WILEY. - 1388-9842 .- 1879-0844. ; 22:9, s. 1504-1524
-
Tidskriftsartikel (refereegranskat)abstract
- Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position statement examines the role of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging and computed tomography in the management of cancer patients. The Imaging and Cardio-Oncology Study Groups of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the ESC have evaluated the current evidence for the value of modern CV imaging in the cardio-oncology field. The most relevant echocardiographic parameters, including global longitudinal strain and three-dimensional ejection fraction, are proposed. The protocol for baseline pre-treatment evaluation and specific surveillance algorithms or pathways for anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor tyrosine kinase inhibitors, BCr-Abl tyrosine kinase inhibitors, proteasome inhibitors and immune checkpoint inhibitors are presented. The indications for CV imaging after completion of oncology treatment are considered. The typical consequences of radiation therapy and the possibility of their identification in the long term are also summarized. Special populations are discussed including female survivors planning pregnancy, patients with carcinoid disease, patients with cardiac tumours and patients with right heart failure. Future directions and ongoing CV imaging research in cardio-oncology are discussed.
|
|
